Linkedin Twitter
Contact

Partnered Pipeline

Focus Is Our Strength

Technology out-licensing is the primary focus of our corporate strategy where we leverage our proprietary platform to deliver best-in-class targeted cancer therapeutics from partner antibodies.
See our announced deals and how to collaborate with us.

Next-Generation ADCs being developed under License Agreements

Partner
Program
(Target)
Preclinical
Phase 1
Pivotal (Phase 2/3)
Partner / Licensee
IBI343 (Claudin 18.2)
targeting
Partner / Licensee
MRG004A (TF)
targeting
Partner / Licensee
MGC026 (B7-H3)
targeting
MGC028 (ADAM9)
targeting
Partner / Licensee
XMT-1660 (B7-H4)
targeting
Partner / Licensee
JNJ_Logo_Shorthand_Red_RGB
in collaboration with Mersana Therapeutics, Inc.
Multiple
Partner / Licensee
2x
Partner / Licensee
KIVU-107
KIVU-305
KIVU-202
Partner / Licensee
2x
Partner / Licensee
CKD-703 (c-MET)
Partner / Licensee
Partner / Licensee
Partner / Licensee
Partner / Licensee
SOT-109
Partner / Licensee

Next-Generation ADCs being developed that contain Synaffix Technology

Organization
Program
(Target)
Preclinical
Phase 1
Pivotal (Phase 2/3)
Organization

National Cancer Institute*

*Sponsor of clinical trial of ADC containing Synaffix technology; this clinical trial is not subject to any license agreement between NCI and Synaffix

ADCT-701 (DLK-1)

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace® Polar Spacer

Forming an integral part of every toxSYN®

linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace
HydraSpace®

GlycoConnect®  design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect®

GlycoConnect® ADCs
Metal-Free Click Conjugation
Enzymatic ADCs (Review)
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1

toxSYN® Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
toxSYN®
Linker-Payload		 Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent		 Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors		 Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect® and HydraSpace® ** N-6-aminohexanoyl-maytansine (Ahx-maytansine)